Urinary Incontinence & Pelvic Organ Prolapse Devices and Equipment Market Report 2026

The urinary incontinence & pelvic organ prolapse devices and equipment market size has grown strongly in recent years. It will grow from $4.06 billion in 2025 to $4.28 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to rising incidence of urinary incontinence disorders, growing awareness of pelvic health conditions, increased availability of clinical treatment options, wider acceptance of medical devices for ui management, expansion of gynecological care services.

The urinary incontinence & pelvic organ prolapse devices and equipment market size is expected to see strong growth in the next few years. It will grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing aging population globally, rising preference for non-invasive therapies, expansion of home healthcare adoption, growing investments in women’s health technologies, increasing demand for advanced pelvic floor rehabilitation devices. Major trends in the forecast period include increasing adoption of minimally invasive treatment devices, rising demand for non-surgical management solutions, growing use of electrical stimulation therapies, expansion of patient-centric home-use devices, enhanced focus on comfort and biocompatibility.

The growing geriatric population is expected to drive the growth of the urinary incontinence and pelvic organ prolapse devices and equipment market in the coming years. The geriatric population refers to individuals aged 65 years and older, and its expansion is largely attributed to increased life expectancy resulting from advances in healthcare and improved living standards. Older adults are more susceptible to conditions such as urinary incontinence and pelvic organ prolapse due to age-related weakening of pelvic floor muscles, hormonal changes, and comorbidities, thereby increasing the need for specialized medical devices and equipment to manage these disorders. For instance, in October 2023, according to HelpAge International, a non-governmental organization focused on the rights of older people, it is projected that by 2050, around 80% of the world’s older population will be living in low- and middle-income countries. This rapid growth in the elderly population is significantly boosting demand for urinary incontinence and pelvic organ prolapse devices and equipment globally.

Major companies operating in the urinary incontinence and pelvic organ prolapse devices and equipment market are emphasizing technological advancements such as patient-specific device customization, precise anatomical modeling, advanced 3D printing, and non-invasive therapeutic support solutions to improve comfort, treatment effectiveness, and long-term pelvic floor outcomes. Patient-specific device customization allows healthcare providers to design pessaries and support devices tailored to an individual’s unique anatomy, resulting in better fit, fewer complications, and reduced reliance on trial-and-error fitting methods. For instance, in March 2024, Cosm Medical, a Canada-based women’s health technology company, introduced an advanced 3D-printed pessary solution called Gynethotics, aimed at transforming pelvic organ prolapse management. By utilizing detailed digital measurements of a patient’s pelvic anatomy, Gynethotics provides custom-fitted support devices that deliver enhanced comfort, stability, and therapeutic performance compared to conventional pessaries. According to Dr. Bilal Iftikhar Chughtai, this personalized approach has the potential to substantially improve patient satisfaction, simplify the fitting process, and lower the need for invasive surgical procedures, representing a significant advancement in non-surgical pelvic floor care.

In September 2023, Caldera Medical, Inc., a U.S.-based women’s health medical device company, acquired Atlantic Therapeutics for an undisclosed amount. Through this acquisition, Caldera Medical aims to broaden its women’s health portfolio by integrating Atlantic Therapeutics’ non-invasive, FDA-cleared Innovo pelvic floor strengthening technology, strengthening its portfolio of first-line therapies for stress urinary incontinence. Innovo uses advanced neuromuscular electrical stimulation to strengthen pelvic floor muscles without the need for internal probes, offering a clinically proven, patient-friendly treatment option. Atlantic Therapeutics is an Ireland-based company specializing in non-invasive pelvic floor strengthening and neuromuscular stimulation solutions for women.

Major companies operating in the urinary incontinence & pelvic organ prolapse devices and equipment market are Boston Scientific Corporation, Coloplast A/S, Ethicon US, Becton Dickinson and Company, Johnson & Johnson, Teleflex Incorporated, Medtronic plc, COVIDien, Cook Medical, Neomedic International, CooperSurgical, MedGyn, Personal Medical Corp, Integra LifeSciences, Panpac Medical, Medesign, Smiths Medical Inc., Thomas Medical, Kangge Medical, Dr. Arabin GmbH & Co. KG, American Medical Systems Inc., Caldera Medical Inc., Intuitive Surgical, InControl Medical LLC, Atlantic Therapeutics Ltd., Axonics Modulation Technologies, Convatec Group plc, Laborie, NUVO Group, Pelvalon, pfm medical, Promedon, Prosurg Inc., UROMED Kurt Drews KG, Verathon Inc., Vitality Medical, Women's Choice Pharmaceuticals, Zimmer Biomet Holdings Inc.

North America was the largest region in the urinary incontinence & pelvic organ prolapse devices and equipment market in 2025. Western Europe was the second-largest region in the urinary incontinence & pelvic organ prolapse devices and equipment market report. The regions covered in the urinary incontinence & pelvic organ prolapse devices and equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary incontinence & pelvic organ prolapse devices and equipment market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

Tariffs are influencing the urinary incontinence and pelvic organ prolapse devices market by increasing costs of imported medical-grade polymers, electronic stimulation components, surgical implants, and precision manufacturing equipment. Healthcare providers in North America and Europe are most affected due to reliance on imported specialized devices, while Asia-Pacific faces higher production costs for export-focused manufacturing. These tariffs are contributing to higher device prices and procurement delays. However, they are also promoting domestic manufacturing, localized sourcing of medical components, and innovation in cost-effective treatment solutions.

The urinary incontinence & pelvic organ prolapse devices and equipment market research report is one of a series of new reports that provides urinary incontinence & pelvic organ prolapse devices and equipment market statistics, including urinary incontinence & pelvic organ prolapse devices and equipment industry global market size, regional shares, competitors with a urinary incontinence & pelvic organ prolapse devices and equipment market share, detailed urinary incontinence & pelvic organ prolapse devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the urinary incontinence & pelvic organ prolapse devices and equipment industry. This urinary incontinence & pelvic organ prolapse devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urinary incontinence & pelvic organ prolapse devices and equipment are used in the treatment of pelvic organ prolapse and urinary incontinence. Urinary incontinence (UI), also known as involuntary urination, is defined as uncontrolled leakage of urine caused by an overactive bladder. Pelvic organ prolapse (POP) is caused by defects in the supporting structures of the vagina.

These devices can be categorized into two main types such as urinary incontinence devices and pelvic organ prolapse devices. Urinary incontinence devices encompass items like artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters, which are utilized to address urinary incontinence. In contrast, pelvic organ prolapse devices include vaginal mesh and vaginal pessaries, designed to manage pelvic organ prolapse. Urinary incontinence can manifest in various forms, including stress incontinence, urge incontinence, overflow incontinence, and functional incontinence. These devices find applications across different healthcare settings, such as hospitals, clinics, ambulatory surgical centers, and for at-home use.

The urinary incontinence & pelvic organ prolapse devices and equipment market consist of sales of artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters that are used for the treatment of pelvic organ prolapse and urinary incontinence. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.